Our Stories
Latest News
Innovation
Caring & Giving
Personal Stories
Health & Wellness
Our Heritage
Our Company
About J&J
Our Credo
Our Leadership Team
Corporate Governance
Diversity & Inclusion
Empowering Women
Innovation at J&J
Office of the Chief Medical Officer
J&J Health and Wellness Solutions
Policies & Statements
Code of Business Conduct
Corporate Reports
Products
Consumer Products
Medical Devices
Pharmaceutical Products
Procurement
Value Pillars
Supplier Diversity
Supplier Standards
Careers
What We Do
How We Hire
Job Spotlight
Employee Benefits
Students
Innovation
Career Stories
Media Center
Investors
Corporate Governance
Quarterly Results
SEC Filings
News Releases
Pharmaceutical Pipeline
2016 Health for Humanity Report
Stock Information
Webcasts & Presentations
Our Societal Impact
Global Community Impact
Global Public Health
Global Environmental Health
Citizenship & Sustainability Reporting
Follow Us
Facebook
Twitter
YouTube
LinkedIn
Explore more Johnson & Johnson sites:
Australia
Argentina
Brazil
Canada
Chile
China
Colombia
Costa Rica
Ecuador
Germany
India
Italy
Japan
Mexico
New Zealand / Pacific
Paraguay
Peru
Philippines
Russia
Switzerland
German
English
French
Italian
Uruguay
United States
Venezuela
Press Release Archive
+
View Filters
All Topics
Caring & Giving
Health & Wellness
Innovation
Our Company
Our Heritage
Our Products
All Dates
Last 30 Days
Last 90 Days
Last Year
Sort by Newest
Sort by Oldest
Products & Operating Company
August 19, 2013
Johnson & Johnson Completes Acquisition Of Aragon Pharmaceuticals, Inc.
Late-Stage Prostate Cancer Treatment Strengthens Oncology Pipeline
Products & Operating Company
August 08, 2013
European Commission Approves VELCADE® As A Frontline Induction Therapy Before Stem Cell Transplantation
Decision could significantly improve transplant outcomes for patients with multiple myeloma
Products & Operating Company
August 07, 2013
STELARA® Receives CHMP Positive Opinion For Treatment Of Psoriatic Arthritis
STELARA Recommended for Approval in Adult Patients with Active Psoriatic Arthritis
Products & Operating Company
August 06, 2013
New Data Confirms Circulating Tumor Cells Are Useful Predictors of Progression-free and Overall Survival
First Study to Demonstrate Value of Circulating Tumor Cell Enumeration in Chinese Metastatic Breast Cancer Patients Published in Annals of Oncology
Products & Operating Company
July 18, 2013
SIMPONI® ARIA™ (golimumab) for infusion Receives FDA Approval for TREATMENT OF MODERATELY TO SEVERELY ACTIVE Rheumatoid arthritis
First Anti-TNF Infusion Therapy Approved in More Than a Decade for Patients Living with Moderately to Severely Active Rheumatoid Arthritis
Financial
July 16, 2013
Johnson & Johnson Reports 2013 Second-Quarter Results
Sales of $17.9 Billion increased 8.5% Versus 2012 Second Quarter;Second-Quarter EPS was $1.33Excluding Special Items, 2013 Second-Quarter EPS of $1.48 Increased 13.8%*
Products & Operating Company
July 16, 2013
Janssen Therapeutics Announces Recipient of Its Second Point Scholarship for LGBT Students
July 15, 2013
Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2013
Products & Operating Company
July 10, 2013
New Drug Application Submitted to U.S. FDA for Ibrutinib in the Treatment of Two B-Cell Malignancies
If approved, ibrutinib will address a high unmet need in relapsed/refractory chronic lymphocytic leukemia and relapsed/refractory mantle cell lymphoma
Products & Operating Company
July 10, 2013
Johnson & Johnson Innovation Announces Finalists of Cognition Challenge
$100,000 awarded for solutions addressing Alzheimer’s disease and cognitive disorders
See More Press Releases